Article
Biology
Lixin Gong, Min Xu, Mengjie Fang, Bingxi He, Hailin Li, Xiangming Fang, Di Dong, Jie Tian
Summary: This study investigated the potential of radiomic features in prostate gland MRI to identify Gleason scores in prostate cancer. The results showed that 2D radiomic features based on prostate gland MRI have stable potential in identifying Gleason scores.
COMPUTERS IN BIOLOGY AND MEDICINE
(2022)
Article
Endocrinology & Metabolism
Victor R. R. Adorno Febles, Yuan Hao, Aarif Ahsan, Jiansheng Wu, Yingzhi Qian, Hua Zhong, Stacy Loeb, Danil V. V. Makarov, Herbert Lepor, James Wysock, Samir S. S. Taneja, William C. C. Huang, Daniel J. J. Becker, Arjun V. V. Balar, Jonathan Melamed, Fang-Ming Deng, Qinghu Ren, Donald Kufe, Kwok-Kin Wong, Dennis O. O. Adeegbe, Jiehui Deng, David R. R. Wise
Summary: This study characterized the tumor immune microenvironment of localized prostate cancer, showing that high-grade prostate cancer (HGPCa) is highly infiltrated by exhausted CD8(+) T cells, myeloid cells, and regulatory T cells. In contrast, low-grade prostate cancer (LGPCa) has a high ratio of activated CD8(+) effector T cells. These findings provide important insights into the immunologic mechanisms of prostate cancer pathogenesis and the potential for immunotherapy.
Article
Oncology
Shuo Wang, Yongpeng Ji, Jinchao Ma, Peng Du, Yudong Cao, Xiao Yang, Ziyi Yu, Yong Yang
Summary: The role of inflammatory factors, including SII and NLR, in predicting GS and GSU in localized PCa after RP was investigated. The results showed that high levels of SII, NLR, and tPSA were associated with higher GS and GSU rate. Combining SII or NLR with tPSA had better predictive value for GS and GSU compared to NLR, SII, or tPSA alone.
FRONTIERS IN ONCOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Rulon Mayer, Charles B. Simone, Baris Turkbey, Peter Choyke
Summary: This study focused on the relationship among the prostate tumor's shape, volume, and potential aggressiveness. It found that prostate tumor eccentricity, determined by histology or MRI, more accurately predicted Gleason score than prostate tumor volume. Combining tumor eccentricity with volume from histology-based analysis enhanced Gleason score prediction, unlike MRI.
QUANTITATIVE IMAGING IN MEDICINE AND SURGERY
(2022)
Article
Pathology
Chantal Atallah, Ants Toi, Theodorus H. van der Kwast
Summary: Several modifications have been made to the Gleason grading system, including the definition and reporting of GP5, with the addition of sub-patterns over time. The presence of GP5 indicates an unfavorable prognosis, but there is a lack of data on the prognostic impact of individual GP5 sub-patterns.
Article
Medicine, General & Internal
Yiliyasi Yimamu, Xu Yang, Junxin Chen, Cheng Luo, Wenyang Xiao, Hongyu Guan, Daohu Wang
Summary: This study aimed to develop an efficient and reliable prognosis prediction signature for prostate cancer patients. By screening differentially expressed genes and performing regression analysis, a model composed of four genes associated with Gleason score was constructed. Through validation and correlation analysis, the model was proven to have high accuracy and independent prognostic significance for predicting biochemical recurrence.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Medicine, General & Internal
Damian Jaworski, Arkadiusz Gzil, Paulina Antosik, Izabela Zarebska, Joanna Dominiak, Izabela Neska-Dlugosz, Anna Kasperska, Dariusz Grzanka, Lukasz Szylberg
Summary: This study aimed to explore the correlation between Gleason score and pattern and the expression of MLH1, MSH2, MDC1, TP53BP1 proteins in prostate cancer. The results showed that MSH2 and MLH1 protein expression, as well as MDC1 protein expression, were significantly correlated with Gleason score, while TP53BP1 protein expression showed no correlation with Gleason score.
ARCHIVES OF MEDICAL SCIENCE
(2023)
Article
Urology & Nephrology
Hwanik Kim, Jung Kwon Kim, Sung Kyu Hong, Chang Wook Jeong, Ja Hyeon Ku, Cheol Kwak
Summary: This study aimed to evaluate the role of multiparametric magnetic resonance imaging in Gleason score 3 + 4 prostate cancer and found that age, initial prebiopsy PSA level, and the presence of PI-RADS lesion >= 4 were independent predictors of Gleason score upgrading.
WORLD JOURNAL OF UROLOGY
(2021)
Article
Oncology
Edward Christopher Dee, Vinayak Muralidhar, Melaku A. Arega, Amar U. Kishan, Daniel E. Spratt, Robert T. Dess, Martin T. King, Sybil T. Sha, Patricia Mae G. Santos, Santino S. Butler, Nina N. Sanford, Paul L. Nguyen, Brandon A. Mahal
Summary: This study aimed to evaluate the association between rates of treatment noncompletion and RT fractionation schedules among men with localized prostate cancer. The results showed that SBRT was associated with lower rates of RT noncompletion, while African American race was associated with greater rates of treatment noncompletion.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Article
Chemistry, Multidisciplinary
Francesco Mercaldo, Maria Chiara Brunese, Francesco Merolla, Aldo Rocca, Marcello Zappia, Antonella Santone
Summary: This paper proposes an approach for automatic Gleason score classification using radiomic features and machine learning techniques, aiming to improve risk stratification and detection of prostate cancer.
APPLIED SCIENCES-BASEL
(2022)
Article
Pathology
Xingran Jiang, Xiumei Hu, Yajuan Gu, Yunlong Li, Mulan Jin, Hongying Zhao, Ruixia Gao, Zhan Huang, Jun Lu
Summary: This study investigated the profile of HRR gene mutations in Chinese localized and locally advanced prostate cancer patients and found that 12.16% of patients had HRR gene mutations. The mutations occurred in seven HRR-related genes, with patients typically having higher Gleason grade and risk level.
PATHOLOGY RESEARCH AND PRACTICE
(2021)
Article
Endocrinology & Metabolism
Oluyemi S. Falegan, Keith Jarvi, Hans J. Vogel, M. Eric Hyndman
Summary: The study suggests that seminal plasma metabolomics profiling of seminal fluid is a promising means of differentiating indolent from aggressive prostate cancer. Particularly, levels of lysine and serine may be able to differentiate between different grades of the disease.
Article
Oncology
Xiao-Ping Qin, Qi-Ji Lu, Cheng-Huizi Yang, Jue Wang, Jian-Fan Chen, Kan Liu, Xin Chen, Jing Zhou, Yu-Hang Pan, Yong-Hong Li, Shan-Cheng Ren, Jiu-Min Liu, Wei-Peng Liu, Hui-Jun Qian, Xian-Lin Yi, Cai-Yong Lai, Li-Jun Qu, Xin Gao, Yu-Sheng Xu, Zheng Chen, Yu-Min Zhuo
Summary: This study determined the predictive value of CRMP4 promoter methylation in low-risk prostate cancer patients for an upgrade of Gleason Score (GS) to ≥ 8 after radical prostatectomy.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Yuan Zhou, Changming Lin, Zhihua Hu, Cheng Yang, Rentao Zhang, Yinman Ding, Zhengquan Wang, Sha Tao, Yanmei Qin
Summary: The study found that for PCa patients with Gleason score 8, those with Gleason 5 + 3 had significantly worse overall survival and cancer-specific survival. By reclassifying the subgroups with Gleason score 4 and 5, the study concluded that PCa patients may have three different survival subgroups.
Article
Cell Biology
Neslisah Seyrek, Eva Hollemans, Susanne Osanto, Rob C. M. Pelger, Henk G. van der Poel, Elise Bekers, Chris H. Bangma, John Rietbergen, Monique J. Roobol, Ivo G. Schoots, Geert J. L. H. van Leenders
Summary: This study showed that in GG2 prostate cancer patients, the GP4 percentage was related to the presence of IC/IDC and TP5, with IC/IDC being an independent predictor for BCRFS while GP4 percentage and TP5 were not.
Review
Oncology
Catherine H. Marshall, Lukasz P. Gondek, Jun Luo, Emmanuel S. Antonarakis
Summary: Clonal hematopoiesis of indeterminate potential (CHIP) refers to the expansion of cells with acquired somatic alterations in the hematopoietic lineage, which is associated with hematologic malignancies and nonmalignant diseases. It is commonly detected incidentally in solid tumor patients' liquid and tissue biopsies. CHIP can also interfere with DNA sequencing results and further research is needed to explore its impact on treatment selection and outcomes for solid tumor patients.
Article
Oncology
Umang Swami, Ryon P. Graf, Roberto H. Nussenzveig, Virginia Fisher, Hanna Tukachinsky, Alexa B. Schrock, Gerald Li, Jeffrey S. Ross, Nicolas Sayegh, Nishita Tripathi, Vinay Mathew Thomas, Geoffrey R. Oxnard, Emmanuel S. Antonarakis, Neeraj Agarwal
Summary: In patients with de novo metastatic castration-sensitive prostate cancer (dn-mCSPC), SPOP mutations were associated with improved outcomes when treated with androgen receptor axis-targeted therapies (ARAT), but not with docetaxel.
CLINICAL CANCER RESEARCH
(2022)
Editorial Material
Urology & Nephrology
Editorial Eugene Shenderov, Emmanuel S. Antonarakis
Article
Endocrinology & Metabolism
Christopher T. Su, Emily Nizialek, Jacob E. Berchuck, Panagiotis J. Vlachostergios, Ryan Ashkar, Alexandra Sokolova, Pedro C. Barata, Rahul R. Aggarwal, Rana R. McKay, Neeraj Agarwal, Heather M. McClure, Nellie Nafissi, Alan H. Bryce, Oliver Sartor, Nicolas Sayegh, Heather H. Cheng, Nabil Adra, Cora N. Sternberg, Mary-Ellen Taplin, Marcin Cieslik, Ajjai S. Alva, Emmanuel S. Antonarakis
Summary: PARP inhibitors (PARPi) are standard treatment for mCRPC patients with specific mutations, but response may differ in patients with ATM and BRCA2 mutations. We investigated differences in response to taxanes, which may inform treatment sequencing decisions.
Article
Oncology
Santosh Gupta, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, David M. Nanus, Emmanuel S. Antonarakis, Daniel C. Danila, Russell Z. Szmulewitz, Richard Wenstrup, Andrew J. Armstrong
Summary: PSMA-targeted radioligand therapy has significantly improved clinical outcomes in men with mCRPC. A liquid biopsy characterizing PSMA expression could be useful in guiding optimal therapy.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Emmanuel S. Antonarakis, Sumit K. Subudhi, Christopher M. Pieczonka, Lawrence I. Karsh, David I. Quinn, Jason M. Hafron, Helen M. Wilfehrt, Matthew Harmon, Nadeem A. Sheikh, Neal D. Shore, Daniel P. Petrylak
Summary: The purpose of this study was to investigate the impact of sequential or concurrent administration of androgen receptor-targeting agents (ARTAs) on sipuleucel-T immune response and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC). The results showed that the median OS remained consistent regardless of whether the agents were administered sequentially or concurrently, and sipuleucel-T induced an immunologic prime-boost effect after initial exposure, even when combined with ARTAs.
CLINICAL CANCER RESEARCH
(2023)
Review
Pharmacology & Pharmacy
Adel Mandl, Mark C. Markowski, Michael A. Carducci, Emmanuel S. Antonarakis
Summary: The BET family of proteins are crucial in activating oncogenic networks in different cancers. Therapeutic targeting of BET proteins has shown potential in treating metastatic castration-resistant prostate cancer. However, clinical success has been limited due to treatment-associated toxicities, drug resistance, and a lack of biomarkers.
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2023)
Article
Oncology
Michael J. Morris, Glenn Heller, David W. Hillman, Olivia Bobek, Charles Ryan, Emmanuel S. Antonarakis, Alan H. Bryce, Olwen Hahn, Himisha Beltran, Andrew J. Armstrong, Lawrence Schwartz, Lionel D. Lewis, Jan H. Beumer, Brooke Langevin, Eric C. McGary, Paul T. Mehan, Amir Goldkorn, Bruce J. Roth, Han Xiao, Colleen Watt, Mary-Ellen Taplin, Susan Halabi, Eric J. Small
Summary: The purpose of this study was to determine whether the addition of abiraterone acetate and prednisone (AAP) to enzalutamide prolongs overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) in the first-line setting. The results showed that the addition of AAP did not provide a statistically significant benefit in OS compared to enzalutamide treatment alone.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Editorial Material
Oncology
Emmanuel S. Antonarakis, Wassim Abida
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Emmanuel S. Antonarakis, Se Hoon Park, Jeffrey C. Goh, Sang Joon Shin, Jae Lyun Lee, Niven Mehra, Ray McDermott, Nuria Sala-Gonzalez, Peter C. Fong, Richard Greil, Margitta Retz, Juan Pablo Sade, Patricio Yanez, Yi-Hsiu Huang, Stephen D. Begbie, Rustem Airatovich Gafanov, Maria De Santis, Eli Rosenbaum, Michael P. Kolinsky, Felipe Rey, Kun-Yuan Chiu, Guilhem Roubaud, Gero Kramer, Makoto Sumitomo, Francesco Massari, Hiroyoshi Suzuki, Ping Qiu, Jinchun Zhang, Jeri Kim, Christian H. Poehlein, Evan Y. Yu
Summary: This study evaluated the efficacy of pembrolizumab plus olaparib compared to a next-generation hormonal agent (NHA) for heavily pretreated mCRPC patients. The results showed that pembrolizumab plus olaparib did not significantly improve rPFS or OS. The study was stopped for futility and no new safety signals were observed.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Endocrinology & Metabolism
Ali. T. T. Arafa, Leah. R. R. Blader, Karan Ramakrishna, Jeff Engle, Charles. J. J. Ryan, Nicholas. A. A. Zorko, Gautam Jha, Emmanuel. S. S. Antonarakis
Summary: This study evaluated the impact of androgen deprivation therapy (ADT) cessation in patients starting abiraterone for castration-resistant prostate cancer. The results showed that abiraterone alone was associated with comparable clinical outcomes to abiraterone plus ADT. Further prospective studies are needed to assess the impact of abiraterone alone on treatment outcomes and cost savings.
Review
Endocrinology & Metabolism
Ali T. T. Arafa, Aditya Jain, Pavel Skrobanek, Brad Humphrey, Jerry W. W. Froelich, Emmanuel S. S. Antonarakis
Summary: This study assessed the impact of Piflufolastat F-18 (18F-DCFPyL) prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging on clinical practice. The results showed that this technology significantly influenced the initial staging, biochemical recurrence, and restaging of metastatic prostate cancer.
Review
Oncology
Angela Y. Y. Jia, Ana P. Kiess, Qiubai Li, Emmanuel S. Antonarakis
Summary: The discovery of small molecules targeting the extracellular domain of PSMA has advanced diagnostic imaging and precision radiopharmaceutical therapies. This review presents existing data and ongoing clinical evaluations of PSMA-based imaging in the management of prostate cancer. It also discusses clinical studies on PSMA-based radiopharmaceutical therapy and forthcoming trials on early disease states. Multidisciplinary collaboration in trial design and therapeutic administration is crucial for the continued progress of this radiotheranostics field.
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Review
Oncology
Sree M. Lanka, Nicholas A. Zorko, Emmanuel S. Antonarakis, Pedro C. Barata
Summary: The development of immune checkpoint inhibitors (ICIs) has revolutionized the treatment landscape of several genitourinary malignancies, but the utility of immunotherapies in prostate cancer has been limited due to its immunologically cold tumor terrain. Pembrolizumab is currently the only approved ICI for metastatic castration resistant prostate cancer (mCRPC) in a select group of patients. Future research is exploring combination approaches with ICIs and other treatments to enhance their efficacy in mCRPC. Additionally, alternative checkpoint inhibitors like B7-H3 hold promise in expanding the treatment options for mCRPC.
Article
Medicine, Research & Experimental
Laura A. Sena, Rajendra Kumar, David E. Sanin, Elizabeth A. Thompson, D. Marc Rosen, Susan L. Dalrymple, Lizamma Antony, Yuhan Yang, Carolina Gomes-Alexandre, Jessica L. Hicks, Tracy Jones, Kiara A. Bowers, Jillian N. Eskra, Jennifer Meyers, Anuj Gupta, Alyza Skaist, Srinivasan Yegnasubramanian, Jun Luo, W. Nathaniel Brennen, Sushant K. Kachhap, Emmanuel S. Antonarakis, Angelo M. De Marzo, John T. Isaacs, Mark C. Markowski, Samuel R. Denmeade
Summary: This study identifies high androgen receptor (AR) activity as a predictive biomarker for response to bipolar androgen therapy (BAT) and supports a treatment paradigm for prostate cancer involving alternating between AR inhibition and activation.
JOURNAL OF CLINICAL INVESTIGATION
(2022)